Recruiting Atopic Dermatitis Studies in Ocala
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
This is a global, multi-center, Phase 3 study that is randomized 2:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherap...
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tu...
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including lo...
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up...
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors....
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
The primary purpose of the study is evaluate the effect of brensocatib compared with placebo....
A Study of IBI363 in Subjects with Advanced Solid Malignancies
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies....
A Study of LM-24C5 For Advanced Solid Tumors
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors....
About Atopic Dermatitis Clinical Trials in Ocala
Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.
There are currently 8 atopic dermatitis clinical trials recruiting participants in Ocala, FL. These studies are seeking a combined 1,831 participants. Research is being sponsored by PDS Biotechnology Corp., BicycleTx Limited, Tyra Biosciences, Inc and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Atopic Dermatitis Clinical Trials in Ocala — FAQ
Are there atopic dermatitis clinical trials in Ocala?
Yes, there are 8 atopic dermatitis clinical trials currently recruiting in Ocala, FL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Ocala?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Ocala research site will contact you about next steps.
Are clinical trials in Ocala free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Ocala studies also compensate for your time and travel.
What atopic dermatitis treatments are being tested?
The 8 active trials in Ocala are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.
Data updated March 2, 2026 from ClinicalTrials.gov